about
Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.Discovery of diverse and functional antibodies from large human repertoire antibody libraries.Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinityDevelopment and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms.Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity.Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders.Metabolic, anabolic, and mitogenic insulin responses: A tissue-specific perspective for insulin receptor activators.Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody.A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control.Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets.A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library.Thermodynamic benchmark study using Biacore technologyAssessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors
P50
Q33967100-8C7F0E80-6B49-4E20-9E7C-68D8C8335AF5Q34604961-4A9C9BCF-A069-44CC-8D28-6523A2D96C5FQ35095516-B00010E0-3E4C-41C3-B167-AD5AB2147638Q35840270-BA2FF421-72C3-4619-9F51-BB04D8F1CE46Q36923616-7320EA77-BACE-49CD-81BC-8E96F35895EEQ38215993-06751849-3158-499B-BA84-D08AF2D6A66EQ38567479-8A9E1B78-CDAA-4EBA-8CF1-50F420D61608Q41161575-29BD1F30-7270-4E9D-AAAC-F5667EEC7B45Q41540099-ADE69BBD-F0BA-4394-814D-BDCB29641CD2Q41922145-7208EBBC-6F9B-4FA9-BAB0-F43E4E4D17C1Q41966485-803A102D-0EF0-4195-931D-4239A2411BDAQ50073562-C3384F35-E576-43DF-BFB0-424DDECD8AE8Q50245247-8C936E60-AB46-454F-A9AC-787294653554Q57266892-F2674E28-2FEB-4A0C-A14C-213B1519F38CQ90065336-9D584233-7BC8-42C5-A72D-16C2B5040E73
P50
description
researcher ORCID ID = 0000-0001-5009-9369
@en
wetenschapper
@nl
name
Daniel H Bedinger
@ast
Daniel H Bedinger
@en
Daniel H Bedinger
@es
Daniel H Bedinger
@nl
type
label
Daniel H Bedinger
@ast
Daniel H Bedinger
@en
Daniel H Bedinger
@es
Daniel H Bedinger
@nl
prefLabel
Daniel H Bedinger
@ast
Daniel H Bedinger
@en
Daniel H Bedinger
@es
Daniel H Bedinger
@nl
P106
P1153
16068192400
P21
P31
P496
0000-0001-5009-9369